Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest
Open Access
- 4 September 2024
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 13 (9) , 840
Abstract
Multidrug-resistant Candida auris has recently caused major outbreaks in healthcare facilities. Rapid and accurate antifungal susceptibility testing (AST) of C. auris is crucial for proper management of invasive infections. The Commercial Sensititre Yeast One and Vitek 2 methods underestimate or overestimate the resistance of C. auris to fluconazole and amphotericin B (AMB). This study evaluated the AST results of C. auris against fluconazole and AMB by gradient-MIC-strip (Etest) and broth microdilution-based MICRONAUT-AM-EUCAST (MCN-AM) assays. Clinical C. auris isolates (n = 121) identified by phenotypic and molecular methods were tested. Essential agreement (EA, ±1 two-fold dilution) between the two methods and categorical agreement (CA) based on the Centers for Disease Control and Prevention’s (CDC’s) tentative resistance breakpoints were determined. Fluconazole resistance-associated mutations were detected by PCR-sequencing of ERG11. All isolates identified as C. auris belonged to South Asian clade I and contained the ERG11 Y132F or K143R mutation. The Etest–MCN-AM EA was poor (33%) for fluconazole and moderate (76%) for AMB. The CA for fluconazole was higher (94.2%, 7 discrepancies) than for AMB (91.7%, 10 discrepancies). Discrepancies were reduced when an MCN-AM upper-limit value of 4 µg/mL for fluconazole-susceptible C. auris and an Etest upper-limit value of 8 µg/mL for the wild type for AMB were used. Our data show that resistance to fluconazole was underestimated by MCN-AM, while resistance to AMB was overestimated by Etest when using the CDC’s tentative resistance breakpoints of ≥32 µg/mL for fluconazole and ≥2 µg/mL for AMB. Method-specific resistance breakpoints should be devised for accurate AST of clinical C. auris isolates for proper patient management.Keywords
This publication has 55 references indexed in Scilit:
- Candida auris outbreak at a tertiary care hospital during the COVID-19 pandemicAmerican Journal of Infection Control, 2024
- Can daily bathing with 4% chlorhexidine + daily chlorhexidine wipe for 1 week be effective in decolonizing Candida auris colonization?European Journal of Clinical Microbiology & Infectious Diseases, 2023
- Molecular characterization of Candida auris outbreak isolates in Qatar from patients with COVID-19 reveals the emergence of isolates resistant to three classes of antifungal drugsClinical Microbiology and Infection, 2023
- Strategies to Prevent Transmission of Candida auris in Healthcare SettingsCurrent Fungal Infection Reports, 2023
- Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk FactorsInfectious Diseases and Therapy, 2022
- Head‐to‐head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testingInternational Journal of Antimicrobial Agents, 2022
- In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida aurisClinical Microbiology and Infection, 2021
- A clinical predictive model of candidaemia by Candida auris in previously colonized critically ill patientsClinical Microbiology and Infection, 2020
- Comparative evaluation of two matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) systems for the identification of clinically significant yeastsInternational Journal of Infectious Diseases, 2014
- Cryptococcus randhawai sp. nov., a novel anamorphic basidiomycetous yeast isolated from tree trunk hollow of Ficus religiosa (peepal tree) from New Delhi, IndiaAntonie van Leeuwenhoek, 2009